AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that, in connection with the appointment of Rob Bancroft as President and Chief Executive Officer, the Company’s Compensation Committee of the Board of Directors has approved the grant of inducement awards.

Read more at globenewswire.com